Improved Pharma

Improved Pharma is a privately-held, US-based service company that de-risks and accelerates drug development through deep expertise in solid-state chemistry and advanced analytical techniques. Its business model is entirely service-driven, offering specialized contract research to support formulation, patent strategy, and regulatory submissions for small molecule therapeutics. The company leverages proprietary methodologies and high-end instrumentation, including synchrotron-based analysis, to solve complex physical chemistry problems, positioning itself as a niche expert for pharmaceutical clients navigating IP challenges and development hurdles.

Integrated suite of advanced solid-state analytical techniques and proprietary methodologies, with core expertise in synchrotron X-ray diffraction (PDF analysis, structure determination), complemented by comprehensive microscopy, thermal analysis, and spectroscopy for pharmaceutical form characterization.

Competes with large, full-service CROs (e.g., Charles River, Labcorp, Eurofins) that have analytical divisions, and with smaller specialized solid-state chemistry consultancies. Differentiation is achieved through deep synchrotron expertise, thought leadership, and a focus on IP-centric problem-solving.